ASH 2022 | Evaluating the addition of venetoclax to a chemotherapy backbone in pediatric AML patients
Gwen Nichols
• 12 Dec 2022
Gwen Nichols, MD, Leukemia & Lymphoma Society, New York, NY, shares some insights into unmet needs in pediatric acute myeloid leukemia (AML), and further discusses a novel clinical trial which will evaluate the randomized addition of venetoclax to a chemotherapy backbone in children with relapsed AML (NCT05183035). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
